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Most cases of pulmonary arterial hypertension (PAH) are not idiopathic, but rather are attributable to
other disorders. This fact has become increasingly apparent following the recent establishment of
centralised PAH registries in several countries. Yet, this ‘‘secondary’’ PAH has been the subject of even less
research than idiopathic PAH, itself an orphan disease par excellence. Secondary PAH is heterogeneous:
prognosis and response to vasodilator therapy differs substantially between various forms of secondary
PAH, partly as a function of underlying pathophysiology, and cannot simply be extrapolated from data
derived from idiopathic PAH.
This article reviews the commonest secondary causes of PAH, focusing on epidemiology, risk factors,
clinical presentation, treatment options, prognosis, and the role of screening. PAH secondary to chronic
hypoxia, congenital heart disease, connective tissue disorders, liver disease, appetite suppressants and
stimulants, and HIV infection are all considered. Strengths and limitations of available screening tests for
PAH are discussed.
 2010 Elsevier Ltd. All rights reserved.Educational aims
 To review the pathophysiology and clinical features of the
commonest causes of secondary pulmonary arterial hyper-
tension (PAH).
 To review the evidence for efﬁcacy of the available treatment
modalities for PAH, when applied to secondary PAH.
 To understand the strengths and limitations of invasive and
noninvasive screening tests for PAH.
 To understand with which frequency and for which conditions
screening is recommended.
 To develop an understanding of prognosis of the various forms
of secondary PAH.1. Introduction
Pulmonary arterial hypertension (PAH) is deﬁned as a resting
mean pulmonary artery pressure (PAP) 25 mmHg, with normal
left atrial pressure. The incidence of PAH has been estimated at 15
cases per million, of which two thirds are ‘secondary’ PAH.1 Prev-
alence estimates for the various types of secondary PAH have
frequently been made on the basis of echocardiographic studies.þ64 9 6310712.
sher).
c.nz.Echocardiography is probably oversensitive for the diagnosis of
PAH,2,3 and right heart catheterisation (RHC) remains the gold
standard. The recent establishment of national registries of RHC-
conﬁrmed PAH in France and the United Kingdom are allowing
more accurate epidemiologic and prognostic information about
secondary PAH to come to light.1,4
The World Symposium on Pulmonary Hypertension (Venice,
2003) divides PH into ﬁve pathophysiological categories.5 Our review
focuses on secondary causes of pulmonary arterial hypertension
(category 1), including collagen vascular diseases, HIV infection and
anorexigen use. We also review PH related to chronic hypoxia (cate-
gory 2), and some miscellaneous conditions including sarcoidosis. In
the interests of space and brevity, pulmonary venous hypertension
and chronic thromboembolic disease are not reviewed.
2. Diagnostic tests
2.1. Echocardiography
Echocardiography is the test most frequently used to investigate
for suspected PAH. It is noninvasive, and is usually more readily
available than RHC. However, it is probably oversensitive for PAH2,3
and cannot distinguish between arterial and venous hypertension.
At present echocardiography is the best noninvasive test for
diagnosis of PAH, but echocardiographic ﬁndings (positive or
negative) need to be interpreted in combination with clinical clues
such as disproportionately poor exercise capacity, low transfer
coefﬁcient (DLCO) or clinical right heart failure.
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A DLCO that is lowered out of proportion to the degree of lung
disease is widely recognised as suggestive of PAH.6 This pattern can
also occur in mixed obstructive and restrictive lung disease. A
reduced DLCO has been associated with increased risk of PAH in
idiopathic pulmonary ﬁbrosis (IPF),7 systemic sclerosis (SSc)8 and
sarcoidosis.9
Current British Thoracic Society guidelines recommend annual
pulmonary function tests (PFTs) in SSc, proceeding to echocardi-
ography if the DLCO is declining or is disproportionately impaired.6
In ILD, consideration of PAH is also recommended where there is
a disproportionate reduction in DLCO.
2.3. Six minute walk test
The six minute walk test (6MWT) provides both useful prog-
nostic information and an objective baseline measure of functional
limitation which can then be followed to observe its response to
therapeutic interventions. Parameters derived from the 6MWT
have been commonly used to provide endpoints in therapeutic
trials in PAH. Though development of secondary PAH is known to
lower six minute walk distance (6MWD),10–12 the role of the 6MWT
in diagnosing PAH remains largely uninvestigated. A study in
sarcoidosis reported that oxygen saturation< 90% on 6MWT pre-
dicted PAH more accurately than 6MWD, and advocated using
a combination of 6MWTand echocardiography to screen for PAH in
this patient group.9 6MWT may be impractical as a diagnostic test
in those PAH-associated conditions that are marked by musculo-
skeletal disability or poor peripheral perfusion, such as
scleroderma.13
3. Pulmonary hypertension as a complication of hypoxaemia
3.1. Chronic obstructive pulmonary disease (COPD)
Among patients with COPD, mild PAH is common14 and corre-
lates with decline in FEV1. However a subpopulation of patients
have PAH disproportionate to the severity of airﬂow obstruc-
tion.14,15 Postulated mechanisms include emphysematous
destruction of the pulmonary vascular bed, hyperviscosity, in situ
thrombosis, and vascular remodelling due to hypoxic vasocon-
striction or chronic inﬂammation.16
COPDaccounted for 0.8%of cases of PAH in a retrospective studyat
a PAH referral centre.17 Among patients with COPD referred for lung
transplant, 7.4% had disproportionate PAH.14 Among 998 patients
with COPD who underwent RHC, only 2.7% had pulmonary artery
pressure (PAP)> 40 mmHg, and only 1.1% had PAHwith COPD as the
only identiﬁable cause.15 PAH of any degree is an adverse prognostic
indicator in COPD,18 possibly because it usually reﬂects more
advanced lung disease.
Echocardiography is relatively insensitive for COPD-associated
PAH, due probably to the increased distance that ultrasound
waves must penetrate. In a group of patients with advanced lung
disease (mostly COPD), echocardiography could only estimate right
ventricular systolic pressure (RVSP) in 44% of cases, and this
modality misclassiﬁed 48% of patients as having PAH.19 As echo-
cardiography cannot rule PAH-COPD in or out, clinicians must
consider other clues such as disproportionate impairment of DLCO,
6MWD, or clinical right heart function.
Some researchers have studied the role of exhaled biomarkers in
diagnosis of PAH complicating COPD. Levels of endothelin-1 (ET-1)
in exhaled breath condensate and plasma were increased, and
levels of exhaled nitric oxide reduced, in patients with PAH-COPD
compared to other patients with COPD and healthy controls.Moreover, ET-1 levels correlated with PAP and inversely correlated
with FEV1.
20
There are few studies of treatment of PAH-COPD. Long term
nifedipine was not beneﬁcial.21 Pulmonary vasodilators may
worsen hypoxaemia by counteracting hypoxic vasoconstriction and
diverting blood ﬂow to poorly ventilated areas of lung, as reported
in a recent observational study.22 Inhalational delivery may avoid
this problem23: indeed, an randomised trial of 3 months of inhaled
nitric oxide showed haemodynamic improvements in severe
COPD.24
A case of favourable response to bosentan has been reported25;
however bosentan showed no beneﬁcial effects and worsened gas
exchange in an randomised trial among patients with severe
COPD.26 Long-term sildenaﬁl was not associated with any
improvement in haemodynamics or 6MWD in a cohort of 5
patients.27 For the time being, use of pulmonary vasodilators in
PAH-COPD should be avoided outside the context of clinical trials.283.2. Sleep disordered breathing
Sleep disordered breathing (SDB) encompasses a variety of
disorders including obstructive and central sleep apnoea, and
nocturnal alveolar hypoventilation due to obesity (obesity hypo-
ventilation syndrome) or other mechanical respiratory abnormal-
ities. True PAH in the setting of SDB is presumed to be caused by
hypoxic vasoconstriction. In addition, a high proportion of patients
with obstructive sleep apnoea (OSA) have abnormal left ventricular
ﬁlling, which may cause pulmonary venous hypertension.29
Prevalence estimates of PAH in OSA range between 17–53%.30–33
Most PAH attributed to OSA appears to bemild: a systematic review
found that the mPAP was <30 mmHg in all published studies.34
There are few reported estimates of SDB prevalence in PAH: one
small study found that nocturnal oxygen desaturation was very
common in idiopathic pulmonary arterial hypertension (IPAH),
whereas apnoeas and hypopnoeas were rare.35 Desaturation was
associated with diurnal hypoxaemia, desaturation with exercise,
and higher A-a gradients. Diurnal hypoxaemia and nocturnal
desaturation have been identiﬁed as risk factors for PAH in SDB in
a number of studies.30,31,36,37 Body mass index (BMI) is a risk factor
in some studies30,31,36 but not others.32,37 Apnoea–hypopnoea
index is a risk factor in a minority of studies.29,31,32
Successful treatment of OSA with CPAP usually lowers
PAP,29,36,38 even in severe cases.39 No published studies have
examined clinical outcomes in the treatment of PAH-SDB.
The American College of Chest Physicians currently recom-
mends that ‘‘assessment for SDB’’ is undertaken in all patients with
PAH.34 Polysomnography is recommended only if there is clinical
suspicion of OSA however. Conversely, screening for PAH in patients
with OSA is not recommended.3.3. Idiopathic pulmonary ﬁbrosis (IPF)
Information in the prevalence of PAH in IPF is scant, with
reported estimates of up to 84% in echocardiographic studies,40,41
but lower prevalences of 8.1% using RHC.42 PAH also correlates
poorly with lung function test results,7 suggesting that it is not
simply a consequence of severe lung disease.
PAH appears to worsen prognosis in IPF, with a recent retro-
spective study reporting 1 year mortality of 61.2%, versus 19.9% in
patients without PAH.43
Bosentan has been trialled in IPF, but patients with PAH were
excluded.44 In a small open-label trial of IV epoprostenol and sil-
denaﬁl, oxygenation was worsened by epoprostenol and improved
by sildenaﬁl.45 Another open-label study of sildenaﬁl in IPF showed
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resulted in improved haemodynamics in another small study.47
Overall, the use of vasodilators in IPF is not currently justiﬁed
outside of clinical trials. It is recommended that patients awaiting
lung transplantation for IPF have regular echocardiography to
monitor RV function in the event of developing PAH.
3.4. Other interstitial lung diseases
Interstitial lung disease may be idiopathic (the idiopathic
interstitial pneumonias, IIP) or secondary to other conditions such
as connective tissue diseases.
PAH associated with ILD may be a consequence of the hypoxia,
interstitial ﬁbrosis, vascular remodelling and hyperviscosity that
complicate these conditions as they advance. Additionally, and
especially in the case of secondary ILD, PAH may represent a sepa-
rate consequence of the underlying systemic process causing ILD.
Studies in IPF suggest that PAH risk is independent of lung function
impairment.7
3.5. Sarcoidosis
Prevalence estimates for PAH in sarcoidosis have ranged from 1–
28%.48 Most of these estimates have been based on echocardiog-
raphy, but echo ﬁndings seem to correlate acceptably with RHC in
sarcoidosis.49
Most patients listed for lung transplantation for sarcoidosis
have PAH on RHC.50 Risk factors may include lung function
impairment (especially total lung capacity), male gender, and
more severe changes on chest X-ray.48
Sarcoidosis can cause pulmonary hypertension in several ways.
PAH as a nonspeciﬁc consequence of progressive hypoxia and
ﬁbrosis associated with interstitial lung disease seems to account
for most cases,49,51,52 but not all. Several published cases describe
extrinsic compression of large vessels by mediastinal lymphade-
nopathy or mediastinal ﬁbrosis.53 Granulomatous vasculitis is
a common histopathological ﬁnding and seems to preferentially
involve veins.49,54
A subgroup of patients may respond to immunosuppressive
therapy in the absence of vasodilators: there are several reports of
success with corticosteroids.49,55–57 Corticosteroid responsiveness
may confound attempts to study the effects of pulmonary vasodi-
lators in sarcoidosis, as most of the study population will receive
concomitant immunosuppressants.
In a retrospective analysis of 22 patients with sarcoidosis-
associated PAH who were treated with vasodilator therapy,
improved haemodynamics and exercise capacity were seen.58 Most
patients had advanced pulmonary ﬁbrosis, and most also received
immunosuppressive therapy. In another retrospective study, long-
term haemodynamic improvements were seen with sildenaﬁl,
though exercise capacity was unchanged.59 Sustained haemody-
namic and functional improvements were seen in small cohorts
treated with bosentan,60-62 IV epoprostenol,63 and inhaled nitric
oxide.64
PAH caused by compression of large vessels has been success-
fully treated with stenting.65
3.6. Prognosis
The prognosis of sarcoidosis-associated PAH appears somewhat
better than IPAH, although this may depend on which pathophys-
iological mechanism is causing the patient’s PAH. In one cohort of
patients, 3 year transplant-free survival was 74%.58 Unsurprisingly
the presence of PAH worsens prognosis among patients awaiting
lung transplantation for sarcoidosis.Screening patients with sarcoidosis for PAH using 6MWD has
been advocated.9 This seems reasonable in patients with advanced
lung disease; in other cases the prevalence of PAH is still unknown,
and may not be high enough to justify screening in asymptomatic
patients.
3.7. Langerhans cell histiocytosis (LCH)
Severe PAH appears to be ubiquitous in advanced LCH: PAH was
present in 92% of cases of LCH referred for lung transplantation and
was moderate to severe in 73%.66 One study found severe PAH in all
tested patients.67 Severity of PAH appears to be independent of
lung function.67,68 Histology shows a proliferative vasculopathy
affecting muscular arteries, veins and venules; plexiform lesions
were not reported.67
A case of moderately severe LCH-associated PAH improved with
corticosteroid therapy and smoking cessation.69 Overall little has
been published about successful treatment of PAH in this condition.
3.8. Lymphangioleiomyomatosis (LAM)
A cross-sectional echocardiographic study in LAM reported
a prevalence of PAH of 7% at rest, rising to 47% with exercise,70 but
there is no published literature of treatment success.
4. Connective tissue diseases
The establishment of PAH registries has allowed estimates of the
prevalence of connective tissue disease-associated pulmonary
hypertension (PAH-CTD); in the United Kingdom it is estimated at
4.23 per million, with an incidence of 1.55/million/year.4 The esti-
mate from the French national registry is lower at 0.4/million/year.1
The strongest association is with scleroderma, which accounts for
76% of PAH-CTD in the French registry.1 PAH affects 3–16% of
patients with scleroderma,2,71–74 independent of the presence of
ILD.75 PAH is also common in systemic lupus erythematosus (SLE)1
and mixed connective tissue disease (MCTD).72,74,76
Reported risk factors include Raynaud’s syndrome,75,77–80
hypocomplementaemia,81 cryoglobulinaemia,81 anti-Ro,75 anti-
RNP 75,82 and anticardiolipin78,83–85 antibodies, and rheumatoid
factor positivity.75 In systemic sclerosis, anti-Scl 70 antibodies may
be associated with a lower risk of PAH.8
The similarity of the pathologic lesion in PAH-CTD and IPAH, the
female predominance among patients with IPAH, and the associa-
tion of IPAH with autoantibodies and autoimmune conditions86–88
has led to speculation that IPAH might be an autoimmune disease.
This would be supported by examples of patients who initially
present with ‘‘idiopathic’’ PAH, then proceed to develop other
features of a connective tissue disease; however opportunities to
observe this have until now been limited by the shortened life
expectancy of patients with PAH. This situation may change with
more widespread use of pulmonary vasodilator therapy. Observa-
tions of a therapeutic response to immunosuppressive therapy
alone add further weight to this hypothesis.89,90
4.1. Pathophysiology of PAH-CTD
Endothelial cells produce endothelin-1, nitric oxide (NO) and
prostacyclin (PGI, epoprostenol). There is substantial evidence
suggesting that endothelial cells are dysfunctional in PAH-CTD.
Expression of endothelial nitric oxide synthase (eNOS) is reduced
in PAH,91 and among patients with scleroderma expression of eNOS
is also reduced.92
Levels of endothelin-1, a potent vasoconstrictor, promoter of
ﬁbrosis and smooth muscle mitogen with a central role in IPAH
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higher levels are associated with increased risk of PAH.
Anti-endothelial cell antibodies (AECA) have been reported in
association with PAH in SSc,95 MCTD85,96 and SLE,97 and higher
AECA serum levels are associated with increased risk of PAH.95
AECA may be pathogenic: exposure to AECA caused healthy
endothelial cells to increase E-selectin expression96 and
endothelin-1 secretion.97
Anti-ﬁbrillarin antibodies are reported in association with PAH-
SSc and PAH-SLE.83,98 Anti-tissue plasminogen activator antibodies
are associatedwith increased risk of PAH in SSc,99 and are alsomore
common in IPAH.100 Anti-ﬁbrillin-1 antibodies are common in
scleroderma.101
4.2. Treatment of PAH-CTD
In general, treatment practices have been extrapolated from
IPAH. The prevalence of pulmonary veno-occlusive disease may be
increased in patients with PAH-CTD,102 so extra care is required to
exclude evidence of this condition when starting vasodilator
therapy.
4.2.1. Prostacyclin analogues
Patients with PAH-CTD treated with IV epoprostenol have
shown improvements in functional class, 6MWD, and haemody-
namics in short term open-label studies.103–105 Longer-term studies
of IV prostacyclin and inhaled iloprost have suggested clinical and
haemodynamic beneﬁts in PAH-CTD and SSc.106,107
In a post hoc analysis of a double-blind randomised trial of IV
treprostinil versus placebo, patients with PAH-CTD (50% sclero-
derma, 28% SLE, 22% MCTD) showed haemodynamic improve-
ments, a marginal increase in 6MWD, and no improvement in Borg
dyspnoea score.108 No beneﬁt was seen from beraprost in a short
term randomised trial.109
4.2.2. Endothelin-1 receptor antagonists
In cohort studies, long term treatment with the nonselective
endothelin-1 receptor antagonist bosentan improved exercise
capacity and RVSP,110 and was associated with 92% 48-week
survival.111
In a subgroup analysis of an open-label randomised trial of
sitaxsentan versus bosentan, patients with PAH-CTD had better 1-
year survival with sitaxsentan and were less likely to withdraw
from sitaxsentan than bosentan.112
4.2.3. Immunosuppression
There have been several case reports and case series describing
physiological and clinical responses of PAH-CTD to various forms of
immunosuppression alone.75,113–125
4.3. Prognosis of PAH-CTD
A review of hospital discharge records from Scotland found
a median survival of 5.9 years in males and 4.9 years in females.126
Pulmonary involvement is the leading cause of death in
scleroderma127 and MCTD.128 1-year survival in PAH-SSc is only
78%.4 Survival in PAH associated with polymyositis, SLE and MCTD
appears to be better with reported 3-year survival of 100%, 74% and
63% respectively.4
Negative prognostic factors reported in PAH-CTD include
sPAP> 60 mmHg, DLCO< 35% predicted, elevated mean right atrial
pressure, shorter time between diagnoses of CTD and PAH, and
presence of ILD.129,130 Favourable factors include younger age,
female sex, better WHO functional class, and higher mixed venous
oxygen saturation.45. Portopulmonary hypertension
Portopulmonary hypertension (PAH-PH) is deﬁned as pulmo-
nary arterial hypertension in the setting of portal hypertension.131
Prospective studies indicate 1–6% of portal hypertension is
complicated by PAH.132–134 Portal hypertension accounted for 10.4%
of secondary PAH in the French registry1; most patients were male,
though this probably reﬂects the overwhelming male predomi-
nance among cirrhotic patients, and there may in fact still be
a female preponderance.131,135 Other risk factors may include
autoimmune hepatitis135 and mutations in oestrogen signalling
pathways.136
PAH-PH is more commonly conﬁrmed using RHC than most
other forms of PAH, owing to its importance as a prognostic factor
in liver transplantation. Echocardiography again appears over-
sensitive, with reported PPV of 59–65%.133,137 A benign hyper-
dynamic circulatory state is common in liver disease and cannot be
distinguished from PAH-PH on echocardiographic grounds.
Nevertheless echocardiographic screening is advocated where liver
transplantation is being contemplated, provided diagnoses are
conﬁrmed by RHC.138
The pathogenesis of PAH-PH is unclear, and may involve endo-
thelial shear stress, or the effects of vasoconstrictors moving from
the portal to the pulmonary circulation.139 Endothelin-1 levels are
elevated in the pulmonary circulation of patients with PAH-PH140;
however they will often have a better haemodynamic proﬁle than
IPAH owing to elevated systemic prostacyclin and nitric oxide
levels that typify portal hypertension.141,142 This may render some
forms of vasodilator therapy less effective or even hazardous in
PAH-PH.143
Intravenous epoprostenol has been associated with haemody-
namic beneﬁts in short-term144 and long-term107 open-label
studies. A case series showing deterioration in portal hyperten-
sion with worsening splenomegaly after epoprostenol adminis-
tration has also been published.143
Patients with severe PAH-PH have shown improved functional
capacity and haemodynamics in two retrospective cohort studies of
long term bosentan treatment.145,146 Bosentan appeared to have
greater beneﬁcial effects than inhaled iloprost on symptoms, hae-
modynamics, and survival. There are case reports of successful use
of sildenaﬁl147 and combination therapy with iloprost, sildenaﬁl
and bosentan.148
The prognostic implications of PAH-PH are unclear. Some
retrospective studies have suggested a poor outcome,149 others
have not.132 Published estimates of 3-year survival range between
38–89%131,149,150; presence and severity of cirrhosis emerged as
negative prognostic factors.131
6. Hereditary haemorrhagic telangiectasia (HHT)
HHT is a common autosomal dominant disorder where muta-
tions in genes of the TGFb receptor family lead to mucocutaneous
telangiectasia and visceral arteriovenous malformations. Individ-
uals with HHT may develop PAH as a result of the high-output
circulatory state associated with multiple arteriovenous malfor-
mations,151 or as an isolated phenomenon clinically similar to IPAH.
The latter presentation is strongly associated with mutations in the
gene for activin receptor-like kinase-1 (ACVRL1).152,153
True PAH is probably a rare complication of HHT.154 An echo-
cardiographic screening study found evidence of PAH in 12% of
patients with HHT; however only one patient underwent conﬁr-
matory RHC, so the signiﬁcance of this result is unclear. It seems
likely that where HHT is accompanied by signiﬁcant arteriovenous
shunt, pulmonary arterial pressures will be mildly elevated on
echocardiography due to hyperdynamic circulatory state.
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PAH. Cases of successful treatment with long term IV prostacy-
clin155 and bosentan156 have been reported.7. Stimulants and appetite suppressants
In the 1970s, a European epidemic of PAH associated with use of
the amphetamine-like appetite suppressant aminorex led to the
withdrawal of that agent.157 A decade later, the serotonin reuptake
inhibitor fenﬂuramine was also implicated in causing PAH.158 This
was conﬁrmed in a case-control study which found an odds ratio of
23.1 among patients using fenﬂuramine derivatives for over 3
months.159 Fenﬂuramine was withdrawn from sale in 1997. Path-
ogenesis of anorexigen-associated PAH is probably through eleva-
tion of circulating levels of serotonin, a pulmonary vasoconstrictor
and smooth muscle mitogen. Use of other stimulants has also been
associated with risk of PAH, including amphetamine, metham-
phetamine and cocaine.160
Anorexigen-associated PAH accounted for 9.5% of cases of RHC-
conﬁrmed PAH in a national French registry.177% of cases were due
to fenﬂuramine derivatives. The role of echocardiographic
screening for PAH and valvular disease in individuals exposed to
anorexigens is unclear. One published study found evidence of PAH
in 6.7% of screened women, though conﬁrmatory RHC was not
performed.161
Once established, anorexigen-associated PAH appears to follow
a similar clinical course to IPAH,162 leading some commentators to
suggest that anorexigens precipitate rather than cause PAH.162 This
is supported by the detection of BMPR2 mutations in 9–22.5% of
patients with anorexigen-associated PAH.162,1638. Human immunodeﬁciency virus (HIV) infection
HIV infection is a moderately strong risk factor for PAH; about
0.5% of HIV-positive individuals have PAH.164 HIV infection
accounted for 6.2% of cases of secondary PAH in the French registry
data reported by Humbert et al.1 Most patients were male. Patho-
logical studies show plexiform arterial lesions, as in IPAH.165
HIV infection is associated with immune deﬁciency and dysre-
gulation, and HIV-infected lymphocytes and macrophages secrete
inﬂammatory cytokines. Additionally, several connections have been
made between viral antigens and pathogenesis of PAH. The gp120
viral envelope protein stimulates endothelial cells and macrophages
to secrete endothelin-1.166 Nef antigen is found in endothelial cells
from HIV-positive patients,167 and seems to induce those cells to
proliferate.167 Macaques infected with a Nef-expressing strain of
simian immunodeﬁciency virus develop plexiform lesions.167 The tat
viral protein also activates endothelial cells, stimulates angiogenesis,
and suppresses BMPR2 gene expression in vitro.168
A genotyping study of HIV-positive patients with PAH found an
increased frequency of HLA-eDR6 and HLA-DR52 alleles,169
a ﬁnding also noted in diffuse inﬁltrative lymphocytosis
syndrome (DILS), an uncommon immune response to HIV infection
which bears some similarities to Sjo¨gren syndrome.
There is little published literature speciﬁc to the treatment of
HIV-associated PAH (PAH-HIV). A cohort study of bosentan showed
improvements in 6MWD, haemodynamics and functional class at 4
months that were maintained beyond 12 months of followup.170
PAH-HIV appears to run a more aggressive course than IPAH,
with a 1 year survival of 51–73% andmedian survival of 1.3 years.171
PAH is the cause of death in 72% of patients with PAH-HIV.171 A CD4
count< 200 confers a worse prognosis, and highly active anti-
retroviral therapy may reduce the incidence of PAH-HIV by main-
taining immunocompetence.172,1739. Screening
The role of screening is unresolved for many of the conditions
discussed above. Criteria that must be satisﬁed in order to justify
a screening programme include evidence that early detection
improves outcome, existence of a reasonably accurate screening
test, and a risk of the condition that is high enough to compen-
sate for the expense and personal risk associated with screening
procedures.174 Currently screening for secondary PAH is speciﬁ-
cally advocated in scleroderma,175,176 congenital heart disease
with left-to-right shunt, and portal hypertension where liver
transplantation is being considered.176,177 A recent consensus
statement advocates screening with echocardiography in any
disease where PAH is a known complication, proceeding to RHC
for patients with TR velocity >¼ 2.8 m/s and normal right atrial
pressure.176
Screening relies on a clear deﬁnition of the disorder of interest.
This is complicated in PAH: ﬁrst, by the increase in normal
pulmonary artery pressures with age,178 and second, by the rec-
ognised phenomenon of ‘‘proportionate’’ mild or moderate
pulmonary hypertension in association with many cardiorespira-
tory disorders.6 This ‘‘proportionate’’ pulmonary hypertension may
not adversely affect prognosis, although few of the prognostic
studies we have reviewed have stratiﬁed for degree of pulmonary
hypertension. The point where proportionate pressures become
disproportionate has not been deﬁned.6
Owing to the risks and resource limitations associatedwith right
heart catheterisation, echocardiography has been the test most
commonly used to screen for PAH. The problem of false positives in
echocardiographic diagnosis of PAH is well recognised.2,3,19,133,137
This has led to interest in other screening modalities. Several
studies have examined exhaled nitric oxide (ENO) as a screening
test. Three groups have reported that ENO levels are elevated
overall in scleroderma compared with healthy controls, but low-
ered in PAH-SSc.179–181 An inverse correlation between ENO and
PAP was also reported.180,181 A small study of IPAH and anorexigen-
associated PAH found that ENO levels normalised after 3 months of
bosentan therapy.182
Computed tomography/magnetic resonance pulmonary angi-
ography is also promising, with pulmonary artery distensibility
showing high sensitivity and speciﬁcity for PAH.183,184
The vasoactive hormone brain natriuretic peptide (BNP) and its
N-terminal fragment (N-terminal pro-BNP) correlate with haemo-
dynamic parameters and functional status in PAH,185–189 and may
predict prognosis43,185,188 and response to therapy190 in at least
some forms of secondary PAH. The role of BNP or NT-proBNP as
a screening test for PAH, alone or in combination with echocardi-
ography, warrants further research.10. Conclusion
Pulmonary hypertension is a serious and increasingly recog-
nised complication of many respiratory and systemic diseases.
Diagnosis is difﬁcult, as echocardiography, while sensitive, is
a poorly speciﬁc test for PAH. To avoid unnecessarily exposing
patients to the risks of RHC, the combination of echocardiography
with other noninvasive screening tests should continue to be
explored. BNP, ENO and CT/MR pulmonary angiography each show
signs of promise in this regard.
Development of PAH is generally associated with poor prog-
nosis, and secondary PAH is the leading cause of death in some of
the conditions reviewed. For most of the available treatment
modalities, evidence of efﬁcacy is minimal or nonexistent, though
this situation is gradually improving.
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Educational questions
Answer the following questions:
1. In pulmonary arterial hypertension secondary to chronic
obstructive pulmonary disease (COPD), which one of the
following statements is true?
a. Moderate or severe PAH is a very common ﬁnding in end
stage COPD
b. While large randomised trials are lacking, the balance of
available evidence suggests that pulmonary vasodilators
are beneﬁcial
c. For a patient with COPD and an FEV1 of 65% predicted,
a DLCO of 30% predicted is disproportionately low and
suggests the presence of PAH
d. All patients with severe COPD should be screened for
pulmonary hypertension with annual transthoracic
echocardiography.
2. The most widely recommended noninvasive screening test for
PAH in systemic sclerosis is:
a. 6 minute walk test looking at desaturation, dyspnoea, and
distance walked
b. DLCO
c. Brain natriuretic peptide
d. Transthoracic echocardiography
3. In sarcoidosis, which one of the following statements is true?
a. PAH is a very common complication in end stage pulmonary
sarcoidosis
b. There is no relationship between severity of interstitial lung
disease and risk of PAH.
c. Most cases are due to compression of pulmonary vessels by
intrathoracic lymphadenopathy and mediastinal ﬁbrosis
d. While immunosuppression is often effective for sarcoidosis,
it is not effective in treating associated PAH
4. In PAH associated with connective tissue disorders, which one
of the following statements is true?
a. Among patients with systemic sclerosis, PAH is now the
leading cause of death.
b. Mixed connective tissue disorder is the CTD accounting for
the greatest number of cases of PAH.
c. The presence of antibodies to Scl-70 indicates increased risk
of PAH.
d. Female sex is associated with a worse prognosis.
5. In PAH associated with HIV infection, which one of the
following statements is true?
a. The gag viral protein may play a role in pathogenesis by
suppressing expression of the BMPR2 gene product.
b. Prognosis correlates with CD4 count.
c. More of this patient group will die from opportunistic
infections than from PAH.d. In countries where highly active antiretroviral therapy
(HAART) is widely available, PAH is now the leading cause
of death among HIV-positive individuals.References
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